抗CD20单克隆抗体治疗难治性自身免疫性溶血性贫血  

Anti-CD20 Monoclonal Antibody for the Treatment of Refractory Autoimmune Hemolytic Anemia

作　　者：王莉[1] 徐卫[1] 李建勇[1] 谢晓艳[1] 盛瑞兰[1] 

机构地区：[1]南京医科大学第一附属医院血液科,南京210029

出　　处：《中国实验血液学杂志》2007年第2期425-428,共4页Journal of Experimental Hematology

摘　　要：本研究初步观察抗CD20单克隆抗体利妥昔(rituximab)用于治疗难治性自身免疫性溶血性贫血(AIHA)的疗效和安全性。对1例用糖皮质激素、脾切除治疗无效的AIHA患者,采用利妥昔单克隆抗体,375mg/m2,每周1次,共4次,观察溶血症状的改变并监测血红蛋白(Hb)水平及其它检验指标,同时观察有无不良反应发生。结果表明,首次治疗后11天乳酸脱氢酶(LDH)、总胆红素(TBIL)、直接胆红素(IBIL)逐渐下降,第45天降至正常范围;首剂治疗25天后Hb水平比治疗之前升高到95-100g/L以上。治疗后已4月余,患者仍处于缓解状态。治疗过程中未发生明显不良反应。结论:抗CD20单克隆抗体利妥昔用于治疗难治性自身免疫性溶血性贫血是有效而且安全的。To observe the therapeutic effect and safety of rituximab （ anti-CD20 monoclonal antibody） in the treatment of refractory autoimmune hemolytic anemia （AIHA）. One AIHA patient refractory to corticosteriod and splenectomy was treated with rituximab, 375 mg/m^2 weekly for four times, Her hemolytic symptoms, adverse effects, hemoglobin （Hb） concertration and other laboratory data were monitored, The results showed that concentration of lactic dehydrogenase （LDH）, total bilirubin （TBIL） and indirect bilirubin （IBIL） began to decrease at 11 days after the first dose of rituximab, and decreased to normal range after 45 days, Concentration of hemoglobin increased up to 95 - 100 g/L, The patient remained disease-free 4 months after treatment, No adverse effect was found during the process of treatment. It is concluded that anti-CD20 monoclonal antibody （rituximab） is both effective and safe for the treatment of refractory autoimmune hemolytic anemia.

关 键 词：抗CD20单克隆抗体 利妥昔 溶血性贫血 难治性自身免疫性溶血性贫血 

分 类 号：R556.6[医药卫生—血液循环系统疾病]